At presentation, the patient ... of tuberculosis. Systemic examination was unremarkable. Results of blood analyses on presentation are shown in Table 1. The serum sample was negative for HIV ...

May 5, 2025 — Chemists found a way to identify a complex sugar molecule in the cell walls of Mycobacterium tuberculosis ... for testing children and HIV patients, who struggle to ...

TMC207 inhibits the proton pump of mycobacterial ATP synthase, a critical enzyme in the synthesis of ATP for Mycobacterium tuberculosis ... frequently reported by patients treated with TMC207 ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

There is still no cure or effective vaccine for HIV, but scientists have opened up new possibilities in HIV treatment and ...

The 2025 Warren Alpert Foundation Prize has been awarded to three scientists whose discoveries culminated in the development ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

French biotech Abivax might be on the verge of HIV cure and prevention discovery, after achieving a significant reduction of viral load patients during the first 28 days of treatment. The company ...

In the quest to develop an effective HIV vaccine, scientists from Scripps Research have made a significant leap forward. They ...

Gilead’s Yeztugo will offer an alternative to treatments such as daily pills and every-other-month injections.